Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

<table>FMA scores in two groups at baseline, 4, 8, and 12th week (repeated measure analysis). <svg height="10.325" id="M27" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 11.75 10.325" width="11.75" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
</text>
</g>
</g>
</svg> value for groups =.003; <svg height="10.325" id="M28" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 11.75 10.325" width="11.75" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
</text>
</g>
</g>
</svg> value for time &lt;.0001;<svg height="10.325" id="M29" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 16.9625 10.325" width="16.9625" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-67.78,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑃</tspan>
</text>
</g>
</g>
</svg> value for interaction between groups and time for 3 times after intervention =.439.</table>

Stroke Research and Treatment

fig2

Figure 2

Figure 2: Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial 